Effector Therapeutics Inc (EFTR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Effector Therapeutics Inc stock (EFTR) is currently trading at $0.00. Effector Therapeutics Inc PS ratio (Price-to-Sales) is 69.65. Analyst consensus price target for EFTR is $10.00. WallStSmart rates EFTR as Sell.
- EFTR PE ratio analysis and historical PE chart
- EFTR PS ratio (Price-to-Sales) history and trend
- EFTR intrinsic value — DCF, Graham Number, EPV models
- EFTR stock price prediction 2025 2026 2027 2028 2029 2030
- EFTR fair value vs current price
- EFTR insider transactions and insider buying
- Is EFTR undervalued or overvalued?
- Effector Therapeutics Inc financial analysis — revenue, earnings, cash flow
- EFTR Piotroski F-Score and Altman Z-Score
- EFTR analyst price target and Smart Rating
Effector Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Effector Therapeutics Inc (EFTR) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Effector Therapeutics Inc (EFTR) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 117.00% year-over-year
Supporting Valuation Data
Effector Therapeutics Inc (EFTR) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 69.7x annual revenue
Very low institutional interest at 0.23%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Effector Therapeutics Inc (EFTR) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.00) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 117.00%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (69.65) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -947.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -947.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 117.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EFTR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EFTR's Price-to-Sales ratio of 69.65x trades 541% above its historical average of 10.87x (89th percentile), historically expensive. The current valuation is 0% below its historical high of 69.65x set in Feb 2026, and Infinity% above its historical low of 0x in Oct 2024. Over the past 12 months, the PS ratio has expanded from ~0.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Effector Therapeutics Inc (EFTR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Effector Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 675,000 with 117% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 117% YoY, reaching 675,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 786% of revenue (5M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Effector Therapeutics Inc maintain 117%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Effector Therapeutics Inc.
Bottom Line
Effector Therapeutics Inc is a high-conviction growth story with revenue accelerating at 117% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Effector Therapeutics Inc(EFTR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Effector Therapeutics Inc (EFTR) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through the selective modulation of RNA translation. By specifically altering protein synthesis within tumor cells, the company is addressing critical unmet needs in oncology with its innovative small molecule treatments. With a robust and diverse pipeline of candidates under development, Effector Therapeutics is dedicated to advancing precision medicine, ultimately striving to improve treatment outcomes and quality of life for cancer patients in an evolving biotechnology landscape.